Your browser doesn't support javascript.
loading
Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
Sullivan, Keith M; Farraye, Francis A; Winthrop, Kevin L; Willer, David O; Vink, Peter; Tavares-Da-Silva, Fernanda.
Afiliação
  • Sullivan KM; Duke University Medical Center, 200 Trent Dr, Durham, NC 27710, USA. Electronic address: keith.sullivan@duke.edu.
  • Farraye FA; Inflammatory Bowel Disease Center, Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Electronic address: farraye.francis@mayo.edu.
  • Winthrop KL; Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: winthrop@ohsu.edu.
  • Willer DO; GSK Vaccines, 100 Milverton Drive Suite 800, Mississauga, ON, Canada. Electronic address: david.o.willer@gsk.com.
  • Vink P; GSK Vaccines, 14200 Shady Grove Rd, Rockville, MD 20850, USA. Electronic address: peter.e.vink@gsk.com.
  • Tavares-Da-Silva F; GSK Vaccines, Av. Fleming 20, 1300 Wavre, Belgium. Electronic address: fernanda.tavares1@organon.com.
Vaccine ; 41(1): 36-48, 2023 01 04.
Article em En | MEDLINE | ID: mdl-36460534
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacina contra Herpes Zoster / Herpes Zoster Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: America do norte Idioma: En Revista: Vaccine Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacina contra Herpes Zoster / Herpes Zoster Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans País/Região como assunto: America do norte Idioma: En Revista: Vaccine Ano de publicação: 2023 Tipo de documento: Article